Tofacitinib treatment exposure in high-risk and low-risk populations in ORAL Surveillance and RA, PsA, UC development programmes
| ORAL Surveillance (RA) | Tofacitinib development programme | |||
| RA* | PsA | UC | ||
| Overall population | ||||
| N | 2911 | 7964 | 783 | 1157 |
| Exposure (PY) | 10 922 | 23 497 | 2038 | 2814 |
| Follow-up; mean, max (years) | 3.8, 6.1 | 3.0, 10.5 | 2.6, 4.8 | 2.4, 7.8 |
| High-risk: ≥65 years or ever smoked | ||||
| N | 1895 | 3577 | 341 | 444 |
| % | 65.1% | 44.9% | 43.6% | 38.4% |
| Exposure (PY) | 6986 | 9961 | 837 | 1113 |
| Low-risk: <65 years and never smoked | ||||
| N | 1016 | 4198 | 442 | 713 |
| % | 34.9% | 52.7% | 56.4% | 61.6% |
| Exposure (PY) | 3937 | 13 168 | 1201 | 1702 |
PY was calculated from the first dose of tofacitinib to the last contact date in ORAL Surveillance, and from the first dose of tofacitinib to the last dose of tofacitinib for all other development programmes.
*Excluding ORAL Surveillance.
N, number of patients treated with tofacitinib; PsA, psoriatic arthritis; PY, patient-years; RA, rheumatoid arthritis; UC, ulcerative colitis.